Stanford scientists have developed a novel hydrogel for long-term drug delivery of an Activator Protein 1 (AP-1) inhibitor for the prevention of post-surgical abdominal adhesion.
Stanford and IBM researchers have recently patented methods for making a new class of multi-branched macromolecules with well-defined molecular weights and surface structures.